Relmada Therapeutics, Inc. (RLMD), Tuesday announced that the company has secured an exclusive licensing for NDV-01 with Trigone Pharma, Ltd. for the treatment of Non-Muscle Invasive Bladder Cancer.
NDV-01 is currently being evaluated in a Phase 2, single-arm study to assess safety and efficacy. The topline data from the first 20 patients in the study are expected to be presented in April.
The company stated that it continues to evaluate additional strategic product opportunities to leverage the extensive development capability that it has built over the past several years.
In the pre-market hours, Relmada's stock is trading at $0.31, up 3.37 percent on the Nasdaq.
For comments and feedback: editorial@rttnews.com